Targeting alpha-4 integrin with natalizumab for intermediate uveitis associated with multiple sclerosis.

Autor:	Calma AD; Department of Neurosciences, Concord Repatriation General Hospital, Sydney, Australia., Young S; Department of Ophthalmology, Concord Repatriation General Hospital, Sydney, Australia., Sandbach J; Department of Ophthalmology, Prince of Wales Hospital, Sydney, Australia., Riminton S; Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.; Department of Immunology, Concord Repatriation General Hospital, Sydney, Australia., Reddel SW; Department of Neurosciences, Concord Repatriation General Hospital, Sydney, Australia.; Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia., Ramanathan S; Department of Neurosciences, Concord Repatriation General Hospital, Sydney, Australia.; Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.; Translational Neuroimmunology Group, Kids Neuroscience Centre, Faculty of Medicine and Health and Brain and Mind Centre, University of Sydney, Sydney, Australia.
Jazyk:	angličtina
Zdroj:	Multiple sclerosis journal - experimental, translational and clinical [Mult Scler J Exp Transl Clin] 2024 Dec 10; Vol. 10 (4), pp. 20552173241301034. Date of Electronic Publication: 2024 Dec 10 (Print Publication: 2024).
DOI:	10.1177/20552173241301034
Abstrakt:	Intermediate uveitis (IU) may be associated with multiple sclerosis (MS), with both conditions possibly sharing pathogenic mechanisms . Two patients presented with bilateral IU. Despite targeted uveitis treatment with corticosteroids and methotrexate, both had ongoing disease activity with symptoms, and fluorescein angiographic abnormalities. Both were subsequently identified to have radiologically isolated MS in the absence of clinical demyelination. Treatment with natalizumab in isolation, led to rapid and sustained resolution of uveitis, enabling discontinuation of other immunosuppression. This case series adds evidence supporting use of alpha-4 integrins in the treatment of MS-associated uveitis, in addition to its known high-efficacy in MS. Competing Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: SWR has no disclosures relevant to the submitted work. He has received travel support, honoraria, trial payments, research and clinical support to the neurology department or academic projects from NHMRC, MRFF, NBA, Myasthenia Alliance Australia, Lambert Initiative, Beeren foundation, anonymous donors; and from pharmaceutical/biological companies: Alexion, Biogen, CSL, Genzyme, Grifols, Merck, Novartis, Roche, Sandoz, Sanofi, UCB. He is co-founder/shareholder of RxPx health, National IVIG Governance Advisory Council & Specialist Working Group Australia (Neurology) (paid), Australian Medical Services Advisory Committee ad-hoc sub-committee on IVIG (paid), Australian Technical Advisory Group on Immunisation Varicella Zoster working party (unpaid), Medical advisor (unpaid) to various patient and advocacy groups. Funds over the last 5 years including but not limited to travel support, honoraria, trial payments, research and clinical support to the neurology department or academic projects from: NHMRC, MRFF, NBA, Myasthenia Alliance Australia, Lambert Initiative, Beeren foundation, anonymous donors; and from pharmaceutical/biological companies: Alexion, Biogen, CSL, Genzyme, Grifols, Merck, Novartis, Roche, Sandoz, Sanofi, UCB. SuRa has no disclosures relevant to the submitted work. She has received research funding from the National Health and Medical Research Council (NHMRC, Australia), the Petre Foundation, the Brain Foundation, the Royal Australasian College of Physicians, and the University of Sydney. She is supported by an NHMRC Investigator Grant (GNT2008339). She serves as a consultant on an advisory board for UCB and Limbic Neurology, and has been an invited speaker for educational/research sessions coordinated by Biogen, Alexion, Novartis, Excemed and Limbic Neurology. She is on the medical advisory board (non-remunerated positions) of The MOG Project and the Sumaira Foundation. All other authors have no relevant disclosures. (© The Author(s), 2024.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu